The lancet. Diabetes & endocrinology
-
Lancet Diabetes Endocrinol · Jun 2014
Randomized Controlled Trial Multicenter Study Comparative StudyExenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial.
When patients with type 2 diabetes start their first injectable therapy, clinicians can choose between glucagon-like peptide-1 (GLP-1) receptor agonists and basal insulins. In DURATION-3, exenatide once weekly was compared with insulin glargine (henceforth, glargine) as first injectable therapy. Here, we report the results of the final 3-year follow-up. ⋯ Amylin Pharmaceuticals and Eli Lilly.
-
Lancet Diabetes Endocrinol · Jun 2014
Randomized Controlled Trial Multicenter StudyEprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study.
Eprotirome is a liver-selective thyroid hormone receptor agonist that has been shown to lower plasma LDL cholesterol concentrations in previous phase 1 and 2 studies of patients with dyslipidaemia. We aimed to assess the long-term safety and efficacy of 50 μg and 100 μg eprotirome in patients with familial hypercholesterolaemia. ⋯ Karo Bio AB.